Marc J. Williams

Ovarian cancer mutational processes drive site-specific immune evasion

High-grade serous ovarian cancer is a genomically complex malignancy. Here the authors integrate whole-genome sequencing, single-cell RNA sequencing, digital histopathology and multiplexed immunofluorescence across 160 tumour sites from 42 patients, revealing that mutational processes shape site-specific immune evasion.

Ongoing genome doubling shapes evolvability and immunity in ovarian cancer

Single-cell whole-genome sequencing of 30,260 tumour genomes from 70 samples across 41 patients in the SPECTRUM cohort reveals that ongoing whole-genome doubling drives tumour evolvability and immune evasion in high-grade serous ovarian cancer.

Tracking clonal evolution during treatment in ovarian cancer using cell-free DNA

Emergence of drug resistance is the main cause of therapeutic failure in patients with high-grade serous ovarian cancer (HGSOC)